Reviva Narrows Losses, Raises Capital Amidst Going Concern Warning

Ticker: RVPH · Form: 10-Q · Filed: Aug 14, 2025

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Clinical Stage, Going Concern, Capital Raise, Net Loss, R&D Expenses

Related Tickers: RVPH

TL;DR

**RVPH is burning cash and needs more funding by Q1 2026, making it a high-risk bet despite narrowing losses.**

AI Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) reported a net loss of $6.05 million for the three months ended June 30, 2025, an improvement from a net loss of $7.86 million in the same period of 2024. For the six months ended June 30, 2025, the net loss was $12.49 million, compared to $15.29 million in the prior year. Research and development expenses decreased significantly to $3.72 million for the three months ended June 30, 2025, from $5.58 million in 2024, and to $7.84 million for the six months ended June 30, 2025, from $11.37 million in 2024. General and administrative expenses remained relatively stable at $2.35 million for the quarter and $4.77 million for the six-month period. The company's cash and cash equivalents decreased to $10.36 million as of June 30, 2025, from $13.48 million at December 31, 2024. RVPH raised $3.90 million from a June 2025 public offering of common stock and $5.07 million from the issuance of common stock warrants in the same offering, alongside $690,602 from an At-The-Market (ATM) offering. Despite these capital raises, the company faces a working capital deficit of approximately $1.3 million and an accumulated deficit of $176.8 million, raising substantial doubt about its ability to continue as a going concern beyond Q4 2025 without additional funding.

Why It Matters

For investors, RVPH's ability to reduce its net loss and raise capital through public offerings is a positive sign, but the persistent 'going concern' warning and working capital deficit of $1.3 million highlight significant financial instability. The company's reliance on future fundraising to sustain operations beyond Q4 2025 introduces substantial risk, especially in a competitive pharmaceutical landscape where clinical trial success and regulatory approvals are paramount. Employees face uncertainty regarding job security if further funding is not secured, potentially impacting morale and talent retention. Customers and the broader market are affected by the potential delays or discontinuation of promising therapies if RVPH cannot maintain its development efforts, impacting the availability of new treatments for CNS, inflammatory, and cardiometabolic diseases.

Risk Assessment

Risk Level: high — The company explicitly states it has an accumulated deficit of $176.8 million and a working capital deficit of approximately $1.3 million as of June 30, 2025. Furthermore, RVPH's current cash of $10.36 million is only sufficient to cover anticipated outlays through the fourth quarter of 2025, necessitating additional fundraising by Q1 2026, which raises substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and consider RVPH a highly speculative investment due to its explicit 'going concern' warning and reliance on future capital raises. Monitor closely for announcements regarding new financing rounds or strategic partnerships, as failure to secure additional funds by Q1 2026 could lead to significant value erosion or cessation of operations.

Financial Highlights

debt To Equity: N/A
revenue: N/A
operating Margin: N/A
total Assets: $11.63M
total Debt: $0.11M
net Income: -$12.49M
eps: -$0.25
gross Margin: N/A
cash Position: $10.36M
revenue Growth: N/A

Key Numbers

$12.49M — Net Loss (6 months) (Decreased from $15.29M in prior year, indicating improved operational efficiency.)
$10.36M — Cash and Cash Equivalents (As of June 30, 2025, down from $13.48M at Dec 31, 2024, highlighting cash burn.)
$176.8M — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses.)
$1.3M — Working Capital Deficit (As of June 30, 2025, signaling short-term liquidity challenges.)
$7.84M — R&D Expenses (6 months) (Decreased from $11.37M in prior year, reflecting reduced development spending.)
$9.21M — Proceeds from Offerings (Net cash provided by financing activities for six months ended June 30, 2025, crucial for operations.)
68,003,613 — Shares Outstanding (As of August 11, 2025, increased from 46,579,199 at Dec 31, 2024 due to offerings.)
$0.25 — Net Loss Per Share (6 months) (Improved from $0.51 in prior year, despite increased share count.)

Key Players & Entities

REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — registrant
Nasdaq Capital Market (regulator) — exchange for common stock and warrants
Securities and Exchange Commission (regulator) — filing authority
$6.05 million (dollar_amount) — net loss for three months ended June 30, 2025
$7.86 million (dollar_amount) — net loss for three months ended June 30, 2024
$12.49 million (dollar_amount) — net loss for six months ended June 30, 2025
$15.29 million (dollar_amount) — net loss for six months ended June 30, 2024
$10.36 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
$176.8 million (dollar_amount) — accumulated deficit as of June 30, 2025
$1.3 million (dollar_amount) — working capital deficit as of June 30, 2025

FAQ

What is Reviva Pharmaceuticals Holdings, Inc.'s current financial liquidity?

As of June 30, 2025, Reviva Pharmaceuticals Holdings, Inc. had cash and cash equivalents of approximately $10.36 million. However, the company also reported a working capital deficit of approximately $1.3 million, indicating short-term liquidity challenges.

Did REVIVA PHARMACEUTICALS (RVPH) raise capital recently?

Yes, REVIVA PHARMACEUTICALS raised $3.90 million from a June 2025 public offering of common stock and $5.07 million from the issuance of common stock warrants in the same offering. Additionally, the company secured $690,602 from an At-The-Market (ATM) offering during the six months ended June 30, 2025.

What is the net loss for REVIVA PHARMACEUTICALS (RVPH) for the first half of 2025?

For the six months ended June 30, 2025, REVIVA PHARMACEUTICALS (RVPH) reported a net loss of approximately $12.49 million. This represents an improvement compared to the net loss of $15.29 million for the same period in 2024.

What are the primary risks for investors in REVIVA PHARMACEUTICALS (RVPH)?

The primary risks for investors in REVIVA PHARMACEUTICALS (RVPH) include the explicit 'going concern' warning, indicating insufficient cash to fund operations beyond Q4 2025 without additional capital. The company also has a significant accumulated deficit of $176.8 million and a working capital deficit of $1.3 million, highlighting its reliance on future fundraising and the inherent risks of a clinical-stage pharmaceutical company.

How have REVIVA PHARMACEUTICALS' (RVPH) research and development expenses changed?

REVIVA PHARMACEUTICALS' (RVPH) research and development expenses decreased significantly. For the three months ended June 30, 2025, R&D expenses were $3.72 million, down from $5.58 million in 2024. For the six months ended June 30, 2025, R&D expenses were $7.84 million, a reduction from $11.37 million in the prior year.

What is the significance of the 'going concern' warning for REVIVA PHARMACEUTICALS (RVPH)?

The 'going concern' warning for REVIVA PHARMACEUTICALS (RVPH) signifies that management has substantial doubt about the company's ability to continue operations for at least one year from the financial statement issuance date. This is due to insufficient cash on hand to meet operating needs beyond the fourth quarter of 2025, necessitating further capital raises.

What is Reviva Pharmaceuticals' strategy to address its funding needs?

Reviva Pharmaceuticals intends to secure additional funding through public or private equity or debt financings, or other sources, which may include collaborations with third parties. The company acknowledges that adequate additional financing may not be available on acceptable terms or at all.

How many shares of common stock does REVIVA PHARMACEUTICALS (RVPH) have outstanding?

As of August 11, 2025, REVIVA PHARMACEUTICALS (RVPH) had 68,003,613 shares of common stock outstanding. This is an increase from 46,579,199 shares outstanding as of December 31, 2024, primarily due to recent public offerings.

What types of diseases does Reviva Pharmaceuticals focus on developing therapies for?

Reviva Pharmaceuticals is a late-stage pharmaceutical company focused on developing new therapies to address unmet medical needs in the areas of central nervous system ("CNS"), inflammatory, and cardiometabolic diseases.

What was the change in cash and cash equivalents for REVIVA PHARMACEUTICALS (RVPH) during the first half of 2025?

REVIVA PHARMACEUTICALS (RVPH) experienced a net decrease in cash and cash equivalents of $3.11 million for the six months ended June 30, 2025. This brought the total cash and cash equivalents down to $10.36 million from $13.48 million at the beginning of the period.

Risk Factors

Going Concern Uncertainty [high — financial]: RVPH faces substantial doubt about its ability to continue as a going concern beyond Q4 2025. As of June 30, 2025, the company has a working capital deficit of $1.3 million and an accumulated deficit of $176.8 million. Despite recent capital raises totaling $9.21 million from stock offerings and warrants, cash and cash equivalents decreased to $10.36 million from $13.48 million at the end of 2024, indicating a significant cash burn rate.
Dependence on Future Financing [high — financial]: The company's ability to fund its operations and development activities is heavily reliant on its capacity to secure additional financing. The current cash position and ongoing operating losses necessitate continuous access to capital markets or other funding sources to meet its obligations.
High R&D Investment and Clinical Trial Risks [medium — operational]: While R&D expenses decreased to $7.84 million for the six months ended June 30, 2025, from $11.37 million in the prior year, pharmaceutical development is inherently risky and expensive. Clinical trial failures or delays can lead to significant financial losses and impact the company's pipeline and future revenue potential.
Working Capital Deficit [medium — financial]: A working capital deficit of $1.3 million as of June 30, 2025, indicates that current liabilities exceed current assets. This situation poses short-term liquidity challenges, potentially impacting the company's ability to meet its immediate operational and financial obligations.
Dilution from Equity Offerings [medium — financial]: The company has significantly increased its shares outstanding from 46,579,199 at December 31, 2024, to 68,003,613 as of August 11, 2025, due to public offerings and warrant exercises. This substantial dilution can negatively impact the value of existing shareholders' stakes.

Industry Context

Reviva Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sector. This industry is characterized by long development cycles, significant R&D investment, stringent regulatory hurdles (FDA approval), and the constant threat of patent expirations and generic competition. Success hinges on innovation, effective clinical trial execution, and securing substantial funding to bring drug candidates to market.

Regulatory Implications

As a pharmaceutical company, RVPH is subject to extensive regulation by bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in healthcare policy can significantly impact its development timelines, market access, and financial viability. The company must maintain rigorous compliance to navigate these regulatory landscapes.

What Investors Should Do

Monitor Cash Burn and Future Funding
Evaluate R&D Pipeline Progress
Assess Dilution Impact
Scrutinize Working Capital Management

Key Dates

2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing a net loss of $6.05 million for the quarter and $12.49 million for the six months. Cash and cash equivalents stood at $10.36 million, with a working capital deficit of $1.3 million.
2025-06-30: Public Offering and Warrant Issuance — RVPH raised $3.90 million from common stock and $5.07 million from warrants, providing crucial, albeit temporary, liquidity.
2025-08-11: Shares Outstanding Update — Reported 68,003,613 shares outstanding, a significant increase from 46,579,199 at year-end 2024, indicating substantial dilution.
2025-12-31: Projected Going Concern Threshold — The company's financial condition raises substantial doubt about its ability to continue as a going concern beyond Q4 2025 without additional funding.

Glossary

Accumulated Deficit: The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (RVPH has a substantial accumulated deficit of $176.8 million as of June 30, 2025, highlighting its history of unprofitability.)
Working Capital Deficit: Occurs when a company's current liabilities exceed its current assets. It indicates potential short-term liquidity issues. (RVPH reported a working capital deficit of $1.3 million as of June 30, 2025, signaling challenges in meeting short-term obligations.)
Going Concern: An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The 10-Q explicitly states substantial doubt about RVPH's ability to continue as a going concern beyond Q4 2025.)
At-The-Market (ATM) Offering: A type of public offering where a company sells its shares directly into the open market over a period of time, typically at prevailing market prices. (RVPH raised $690,602 through an ATM offering, contributing to its cash position.)
Warrant Liabilities: Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price before its expiration date. They are often issued alongside other securities. (Warrant liabilities decreased from $89,010 at December 31, 2024, to $16,690 at June 30, 2025, partly due to remeasurement gains.)

Year-Over-Year Comparison

Compared to the prior year, Reviva Pharmaceuticals Holdings, Inc. has shown improved operational efficiency, evidenced by a reduced net loss for both the three-month ($6.05M vs $7.86M) and six-month ($12.49M vs $15.29M) periods ending June 30, 2025. This improvement is largely driven by a significant decrease in Research and Development expenses ($7.84M vs $11.37M for six months). However, the company's financial position has weakened, with cash and cash equivalents declining to $10.36M from $13.48M and a growing accumulated deficit now at $176.8M. New risks related to substantial doubt about its going concern status beyond Q4 2025 have emerged due to a working capital deficit of $1.3M.

Filing Stats: 4,353 words · 17 min read · ~15 pages · Grade level 15.2 · Accepted 2025-08-14 16:32:05

Key Financial Figures

$0.0001 — registered Common Stock, par value $0.0001 per share RVPH The Nasdaq Capital M

Filing Documents

rvph20250630_10q.htm (10-Q) — 1207KB
ex_847049.htm (EX-31.1) — 11KB
ex_847050.htm (EX-31.2) — 11KB
ex_847051.htm (EX-32.1) — 8KB
efficacy01.jpg (GRAPHIC) — 42KB
safety01.jpg (GRAPHIC) — 45KB
summsafety01.jpg (GRAPHIC) — 56KB
0001437749-25-026967.txt ( ) — 5945KB
rvph-20250630.xsd (EX-101.SCH) — 51KB
rvph-20250630_def.xml (EX-101.DEF) — 319KB
rvph-20250630_lab.xml (EX-101.LAB) — 264KB
rvph-20250630_pre.xml (EX-101.PRE) — 344KB
rvph-20250630_cal.xml (EX-101.CAL) — 24KB
rvph20250630_10q_htm.xml (XML) — 987KB

Financial Statements (unaudited)

Financial Statements (unaudited) F-1 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 F-1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 F-2 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 F-3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 F-5 Notes to Condensed Consolidated Financial Statements F-6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 1 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 15 Item 4.

Controls and Procedures

Controls and Procedures 15 Part II Other Information 17 Item 1.

Legal Proceedings

Legal Proceedings 17 Item 1A.

Risk Factors

Risk Factors 17 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 18 Item 3. Defaults Upon Senior Securities 18 Item 4. Mine Safety Disclosures 18 Item 5. Other Information 18 Item 6. Exhibits 19

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 10,363,714 $ 13,476,331 Prepaid clinical trial costs 104,447 540,601 Prepaid expenses and other current assets 346,964 666,435 Total current assets 10,815,125 14,683,367 Non-current prepaid clinical trial costs 819,721 819,721 Total Assets $ 11,634,846 $ 15,503,088 Liabilities and Stockholders ' Equity (Deficit) Liabilities Short-term debt $ 113,246 $ 458,154 Accounts payable 4,968,688 6,283,430 Accrued clinical expenses 5,470,185 6,723,719 Accrued compensation 602,592 635,587 Other accrued liabilities 922,592 500,616 Total current liabilities 12,077,303 14,601,506 Warrant liabilities 16,690 89,010 Total Liabilities 12,093,993 14,690,516 Commitments and contingencies (Note 6) Stockholders ' Equity (Deficit) Common stock, par value of $ 0.0001 ; 315,000,000 shares authorized; 68,003,613 and 46,579,199 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 6,800 4,658 Preferred Stock, par value of $ 0.0001 ; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Additional paid-in capital 176,293,553 165,080,964 Accumulated deficit ( 176,759,500 ) ( 164,273,050 ) Total stockholders' equity (deficit) ( 459,147 ) 812,572 Total Liabilities and Stockholders ' Equity (Deficit) $ 11,634,846 $ 15,503,088 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-1 REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses Research and development $ 3,724,755 $ 5,